Treating Penile Cancer in the Immunotherapy and Targeted Therapy Era
While localized penile cancers are typically treated surgically and metastatic penile cancers benefit from standard chemotherapy, there have been studies on the horizon demonstrating immunotherapy as a novel approach to metastatic penile cancers that have failed standard chemotherapy. We report a ca...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Case Reports in Oncological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2019/8349793 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832562517018148864 |
|---|---|
| author | Gavin Hui Sanaz N. Ghafouri John Shen Sandy Liu Alexandra Drakaki |
| author_facet | Gavin Hui Sanaz N. Ghafouri John Shen Sandy Liu Alexandra Drakaki |
| author_sort | Gavin Hui |
| collection | DOAJ |
| description | While localized penile cancers are typically treated surgically and metastatic penile cancers benefit from standard chemotherapy, there have been studies on the horizon demonstrating immunotherapy as a novel approach to metastatic penile cancers that have failed standard chemotherapy. We report a case series of two patients who improved on immunotherapy after progressing with standard chemotherapy regimens. The first case describes a 64-year-old male with a penile mass and significant lymphadenopathy who had surgical resection and adjuvant chemotherapy prior to continued disease progression. He was started on anti-EGFR treatment and improved initially, but he eventually had progression of disease. The second case describes a 79-year-old male with a penile mass who was treated with surgical resection and started on adjuvant chemoradiation, but he developed recurrence and nodal involvement. Therefore, second-line therapy of the PD-L1 inhibitor was started in this patient. There were no available clinical trials for penile cancer patients who progressed beyond the standard surgical therapy and chemotherapy. |
| format | Article |
| id | doaj-art-24fe8f0453054d3da640efe4961c8e0b |
| institution | Kabale University |
| issn | 2090-6706 2090-6714 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Oncological Medicine |
| spelling | doaj-art-24fe8f0453054d3da640efe4961c8e0b2025-02-03T01:22:22ZengWileyCase Reports in Oncological Medicine2090-67062090-67142019-01-01201910.1155/2019/83497938349793Treating Penile Cancer in the Immunotherapy and Targeted Therapy EraGavin Hui0Sanaz N. Ghafouri1John Shen2Sandy Liu3Alexandra Drakaki4UCLA Medicine Education Office, RRUCLA Medical Center, 757 Westwood Plaza, Suite 7501, Los Angeles, CA 90095-7417, USAUCLA Medicine Education Office, RRUCLA Medical Center, 757 Westwood Plaza, Suite 7501, Los Angeles, CA 90095-7417, USAUCLA Medicine Education Office, RRUCLA Medical Center, 757 Westwood Plaza, Suite 7501, Los Angeles, CA 90095-7417, USAUCLA Medicine Education Office, RRUCLA Medical Center, 757 Westwood Plaza, Suite 7501, Los Angeles, CA 90095-7417, USAUCLA Medicine Education Office, RRUCLA Medical Center, 757 Westwood Plaza, Suite 7501, Los Angeles, CA 90095-7417, USAWhile localized penile cancers are typically treated surgically and metastatic penile cancers benefit from standard chemotherapy, there have been studies on the horizon demonstrating immunotherapy as a novel approach to metastatic penile cancers that have failed standard chemotherapy. We report a case series of two patients who improved on immunotherapy after progressing with standard chemotherapy regimens. The first case describes a 64-year-old male with a penile mass and significant lymphadenopathy who had surgical resection and adjuvant chemotherapy prior to continued disease progression. He was started on anti-EGFR treatment and improved initially, but he eventually had progression of disease. The second case describes a 79-year-old male with a penile mass who was treated with surgical resection and started on adjuvant chemoradiation, but he developed recurrence and nodal involvement. Therefore, second-line therapy of the PD-L1 inhibitor was started in this patient. There were no available clinical trials for penile cancer patients who progressed beyond the standard surgical therapy and chemotherapy.http://dx.doi.org/10.1155/2019/8349793 |
| spellingShingle | Gavin Hui Sanaz N. Ghafouri John Shen Sandy Liu Alexandra Drakaki Treating Penile Cancer in the Immunotherapy and Targeted Therapy Era Case Reports in Oncological Medicine |
| title | Treating Penile Cancer in the Immunotherapy and Targeted Therapy Era |
| title_full | Treating Penile Cancer in the Immunotherapy and Targeted Therapy Era |
| title_fullStr | Treating Penile Cancer in the Immunotherapy and Targeted Therapy Era |
| title_full_unstemmed | Treating Penile Cancer in the Immunotherapy and Targeted Therapy Era |
| title_short | Treating Penile Cancer in the Immunotherapy and Targeted Therapy Era |
| title_sort | treating penile cancer in the immunotherapy and targeted therapy era |
| url | http://dx.doi.org/10.1155/2019/8349793 |
| work_keys_str_mv | AT gavinhui treatingpenilecancerintheimmunotherapyandtargetedtherapyera AT sanaznghafouri treatingpenilecancerintheimmunotherapyandtargetedtherapyera AT johnshen treatingpenilecancerintheimmunotherapyandtargetedtherapyera AT sandyliu treatingpenilecancerintheimmunotherapyandtargetedtherapyera AT alexandradrakaki treatingpenilecancerintheimmunotherapyandtargetedtherapyera |